NAPROXEN DELAYED RELEASE- naproxen tablet

Land: USA

Sprog: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv bestanddel:

NAPROXEN (UNII: 57Y76R9ATQ) (NAPROXEN - UNII:57Y76R9ATQ)

Tilgængelig fra:

Camber Pharmaceuticals

INN (International Name):

NAPROXEN

Sammensætning:

NAPROXEN 375 mg

Indgivelsesvej:

ORAL

Recept type:

PRESCRIPTION DRUG

Terapeutiske indikationer:

Carefully consider the potential benefits and risks of Naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Naproxen delayed-release tablets are indicated: - For the relief of the signs and symptoms of rheumatoid arthritis - For the relief of the signs and symptoms of osteoarthritis - For the relief of the signs and symptoms of ankylosing spondylitis - For the relief of the signs and symptoms of juvenile arthritis Naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION). Naproxen delayed-release tablets are contraindicated in patients with known hypersensitivity to naproxen. Naproxen delayed-release tablets should not be given to

Produkt oversigt:

Naproxen Delayed-release Tablets USP: 375 mg: White Enteric coated, Capsule-shaped, biconvex tablets de-bossed with ‘I 1’ on one side, supplied in bottles of 100’s count (NDC 31722-338-01). Naproxen Delayed-release Tablets USP: 500 mg: White Enteric coated, Capsule-shaped, biconvex tablets de-bossed with ‘I 11’ on one side, supplied in bottles of 100’s count (NDC 31722-339-01) and 500’s count (NDC 31722-339-05). Store at 20° to 25°C (68° to 77°F); [See USP Controlled Room Temperature]. Dispense in tight, light­resistant containers.

Autorisation status:

Abbreviated New Drug Application

Indlægsseddel

Camber Pharmaceuticals
----------
MEDGUIDE
Medication Guide for Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
(See the end of this Medication Guide for a list of prescription NSAID
medicines.)
__________________________________________________________________________
What is the most important information I should know about medicines
called Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs)?
NSAID medicines may increase the chance of a heart attack or stroke
that can lead to death. This chance
increases:
•
with longer use of NSAID medicines
•
in people who have heart disease
NSAID medicines should never be used right before or after a heart
surgery called a “coronary artery
bypass graft (CABG).”
NSAID medicines can cause ulcers and bleeding in the stomach and
intestines at any time during
treatment. Ulcers and bleeding:
•
can happen without warning symptoms
•
may cause death
The chance of a person getting an ulcer or bleeding increases with:
•
taking medicines called “corticosteroids” and “anticoagulants”
•
longer use
•
smoking
•
drinking alcohol
•
older age
•
having poor health
NSAID medicines should only be used:
•
exactly as prescribed
•
at the lowest dose possible for your treatment
•
for the shortest time needed
___________________________________________________________________________
What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines are used to treat pain and redness, swelling, and heat
(inflammation) from medical
conditions such as:
•
different types of arthritis
•
menstrual cramps and other types of short-term pain
Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?
Do not take an NSAID medicine:
•
if you had an asthma attack, hives, or other allergic reaction with
aspirin or any other NSAID
medicine
•
for pain right before or after heart bypass surgery
Tell your healthcare provider:
•
about all of your medical conditions.
•
about all of the medicines you take. NSAIDs and some other medicines
can interact with each
o

Produktets egenskaber

NAPROXEN DELAYED RELEASE- NAPROXEN TABLET
CAMBER PHARMACEUTICALS
----------
NAPROXEN DELAYED-RELEASE TABLETS USP, 375 MG AND 500 MG
Rx only
CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious
cardiovascular
thrombotic events, myocardial infarction, and stroke, which can be
fatal. This risk may
increase with duration of use. Patients with cardiovascular disease or
risk factors for
cardiovascular disease may be at greater risk (see WARNINGS). Naproxen
delayed-
release tablets are contraindicated for the treatment of
peri-operative pain in the setting of
coronary artery bypass graft (CABG) surgery (see WARNINGS).
GASTROINTESTINAL RISK
NSAIDs cause an increased risk of serious gastrointestinal adverse
events including
bleeding, ulceration, and perforation of the stomach or intestines,
which can be fatal.
These events can occur at any time during use and without warning
symptoms. Elderly
patients are at greater risk for serious gastrointestinal events (see
WARNINGS).
DESCRIPTION
Naproxen, USP is a proprionic acid derivative related to the
arylacetic acid group of nonsteroidal anti-
inflammatory drugs.
The chemical names for naproxen, USP is
(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid It has the
following structural formula:
Naproxen, USP has a molecular weight of 230.26 and a molecular formula
of C14H14O3.
Naproxen, USP is an odorless, white to off-white crystalline
substance. It is lipid ¬soluble, practically
insoluble in water at low pH and freely soluble in water at high pH.
The octanol/water partition
coefficient of naproxen at pH 7.4 is 1.6 to 1.8.
Naproxen delayed-release tablets USP are available as enteric coated,
white tablets containing 375 mg
of naproxen and 500 mg of naproxen, USP for oral administration. The
inactive ingredients are
croscarmellose sodium, povidone, colloidal silicon dioxide and
magnesium stearate. The enteric
coating dispersion contains methacrylic acid copolymer dispersion,
talc, titanium dioxide triethyl citrate
and purified water. The dissolution of this enteric-coa